Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Polyvalent Vaccines and Methods for Making Them, 28791 [2024-08361]

Download as PDF Federal Register / Vol. 89, No. 77 / Friday, April 19, 2024 / Notices Dated: April 15, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–08286 Filed 4–17–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License, Inter-Institutional AgreementInstitution Lead: Polyvalent Vaccines and Methods for Making Them AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, on behalf of the Centers for Disease Control and Prevention, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University Health Network, located in Toronto, Canada, its rights to the technologies and the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice. DATES: Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before May 6, 2024 will be considered. ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Ann Marie Flammang Ph.D., Senior Technology Transfer Patent Specialist, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852–9804, phone number 301–761–6682, or annmarie.flammang@nih.gov. SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: United States Provisional Patent Application Number 63/278,467, filed November 11, 2021, entitled ‘‘Polyvalent Vaccines and Methods for Making Them’’ (HHS Reference No. E–091–2024–0–US–01), and Patent Cooperation Treaty Patent Application Number PCT/CA2022/ 051680, filed November 14, 2022, lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 02:06 Apr 19, 2024 Jkt 262001 entitled ‘‘Polyvalent Vaccines and Methods for Making Them’’ (HHS Reference No. E–091–2024–0–PC–01). All patent rights in these inventions have been assigned to University Health Network, University of Liverpool, The Governing Council of the University of Toronto, and Centers for Disease Control and Prevention. The prospective patent license will be for the purpose of consolidating the patent rights to University Health Network, the co-owners of said rights, for commercialization. Consolidation of these co-owned rights is intended to expedite development of the technology, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212. The prospective patent license will be worldwide, exclusive, and may be limited to those fields of use commensurate in scope with the patent rights. It will be sublicensable, and any sublicenses granted by University Health Network will be subject to the provisions of 37 CFR part 404. The technology is a strategy to overcome the challenge of virus heterogeneity against hepatitis C virus (HCV). Using a model of hypervariable region 1 (HRV1) genetic variability and observed discrete, genotypeindependent clusters, sequences were selected to synthesize peptides for vaccination. The pentavalent mixture resulted in an antibody response that was more broadly neutralizing than each individual variant or pooled sera, indicating a synergistic interaction among immune responses to related, but distinct, HVR1 variants. These findings open a new path for the development of an HCV vaccine using sequence complementary variants of genetically divergent HVR1 antigenic epitopes. A method was developed for producing a multivariant vaccine comprised of a plurality of peptides or the nucleic acids encoding them. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Insitute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 28791 confidentially, and may be made publicly available. Complete license applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated: April 15, 2024. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2024–08361 Filed 4–18–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR 6453–N–01] Announcement of Tenant Protection Voucher Funding Awards for Fiscal Year 2023 for the Housing Choice Voucher Program Office of the Assistant Secretary for Public and Indian Housing, HUD. ACTION: Notice of fiscal year 2023 awards. AGENCY: In accordance with the Department of Housing and Urban Development Reform Act of 1989, this document notifies the public of Tenant Protection Voucher (TPV) funding awards for fiscal year (FY) 2023 to public housing agencies (PHAs) under the Section 8 Housing Choice Voucher Program (HCVP). The purpose of this notice is to publish the names, addresses of awardees, and the amount of their non-competitive funding awards for assisting households affected by housing conversion actions, public housing relocations and replacements, and moderate rehabilitation replacements. This notice also includes a link to the TPV awards issued since FY 2020, which can be sorted by PHAs, project name and identification number, by category of TPVs such as Multifamily or Public Housing, and by state and by HUD regions. FOR FURTHER INFORMATION CONTACT: Danielle L. Bastarache, Deputy Assistant Secretary, Office of Public Housing and Voucher Programs, Office of Public and Indian Housing, Department of Housing and Urban Development, 451 Seventh Street SW, Room 4204, Washington, DC 20410–5000, telephone (202) 402–1380. HUD welcomes and is prepared to receive calls from individuals who are SUMMARY: E:\FR\FM\19APN1.SGM 19APN1

Agencies

[Federal Register Volume 89, Number 77 (Friday, April 19, 2024)]
[Notices]
[Page 28791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08361]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License, Inter-Institutional 
Agreement-Institution Lead: Polyvalent Vaccines and Methods for Making 
Them

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, on behalf of the Centers for Disease Control and 
Prevention, Department of Health and Human Services, is contemplating 
the grant of an exclusive, sublicensable patent license to University 
Health Network, located in Toronto, Canada, its rights to the 
technologies and the patent applications listed in the SUPPLEMENTARY 
INFORMATION section of this notice.

DATES: Only written comments and/or applications for a license which 
are received by the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases on or 
before May 6, 2024 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated exclusive patent license 
should be directed to: Ann Marie Flammang Ph.D., Senior Technology 
Transfer Patent Specialist, Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone 
number 301-761-6682, or [email protected].

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement: United States 
Provisional Patent Application Number 63/278,467, filed November 11, 
2021, entitled ``Polyvalent Vaccines and Methods for Making Them'' (HHS 
Reference No. E-091-2024-0-US-01), and Patent Cooperation Treaty Patent 
Application Number PCT/CA2022/051680, filed November 14, 2022, entitled 
``Polyvalent Vaccines and Methods for Making Them'' (HHS Reference No. 
E-091-2024-0-PC-01). All patent rights in these inventions have been 
assigned to University Health Network, University of Liverpool, The 
Governing Council of the University of Toronto, and Centers for Disease 
Control and Prevention.
    The prospective patent license will be for the purpose of 
consolidating the patent rights to University Health Network, the co-
owners of said rights, for commercialization. Consolidation of these 
co-owned rights is intended to expedite development of the technology, 
consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 
200-212.
    The prospective patent license will be worldwide, exclusive, and 
may be limited to those fields of use commensurate in scope with the 
patent rights. It will be sublicensable, and any sublicenses granted by 
University Health Network will be subject to the provisions of 37 CFR 
part 404.
    The technology is a strategy to overcome the challenge of virus 
heterogeneity against hepatitis C virus (HCV). Using a model of 
hypervariable region 1 (HRV1) genetic variability and observed 
discrete, genotype-independent clusters, sequences were selected to 
synthesize peptides for vaccination. The pentavalent mixture resulted 
in an antibody response that was more broadly neutralizing than each 
individual variant or pooled sera, indicating a synergistic interaction 
among immune responses to related, but distinct, HVR1 variants. These 
findings open a new path for the development of an HCV vaccine using 
sequence complementary variants of genetically divergent HVR1 antigenic 
epitopes. A method was developed for producing a multivariant vaccine 
comprised of a plurality of peptides or the nucleic acids encoding 
them.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Insitute of Allergy and Infectious Diseases receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 
404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    Complete license applications submitted in response to this Notice 
will be presumed to contain business confidential information and any 
release of information in these license applications will be made only 
as required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 15, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08361 Filed 4-18-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.